Ro.co vs TMates: Wegovy Pill Access vs Compounded Semaglutide
The Ro.co vs TMates comparison centers on one core choice: Ro.co gives patients access to the FDA-approved Wegovy oral GLP-1 pill with a $39 get-started price, while TMates provides clinically dosed compounded semaglutide at a flat $199/month with 24/7 U.S. doctor access. Early verdict: choose Ro.co if you prioritize an FDA-approved oral option and regulatory clarity; choose TMates if you want a predictable flat monthly price and continuous physician availability.
How Ro.co and TMates differ at a glance
Ro.co and TMates both offer online GLP-1 weight loss care but differ on medication type, pricing model, clinical access, and regulatory status. The most distinctive supported differences are: medication formulation and FDA approval; entry and ongoing pricing; clinician availability and support; and U.S. manufacturing versus branded finished product access.
Medication type and FDA status
Ro.co: Offers access to the Wegovy pill, described as the first and only FDA-approved oral GLP-1 weight loss medication. The platform emphasizes that the Wegovy pill is an FDA-approved finished medication, not compounded. Treatment is available only when a licensed clinician determines it is medically appropriate. Ro.co notes that compounded medications, when offered by others, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
TMates: Offers clinically dosed compounded semaglutide formulated in U.S. facilities. TMates states that compounded semaglutide uses the same active ingredient mechanism as Wegovy and Ozempic but is compounded rather than an FDA-approved finished product. The source explicitly notes that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
See TMates flat $199/month plan
Pricing model and transparency
Ro.co: Promotes a Get Started Online price of just $39 as the entry point. The source emphasizes that branded and FDA-approved medications like the Wegovy pill carry higher ongoing costs than compounded alternatives and that ongoing medication pricing depends on the treatment plan and medication prescribed. Ro.co claims no hidden fees and that pricing is disclosed before you complete your consultation.
TMates: Promotes a flat $199/month price at every dose with no step-up fees as dosage escalates. The source lists variations for multi-month plans but repeatedly points to a straightforward flat-rate model and free shipping. TMates positions this model as budgetable because the monthly rate does not increase with higher therapeutic doses.
Clinician access and patient support
Ro.co: Described as an established, full-service telehealth platform that prescribes FDA-approved medications after licensed clinician review. The source emphasizes brand trust and that treatment is subject to clinician review.
TMates: Highlights 24/7 access to U.S.-based doctors across all 50 states and virtual check-ins for ongoing oversight. The source contrasts actual physician availability against messaging-only support at some competitors and markets continuous availability as a distinction.
Explore TMates clinician access
Comparison table: Ro.co vs TMates
| Criteria | Ro.co | TMates |
|---|---|---|
| Primary medication | Wegovy pill, FDA-approved oral GLP-1 | Clinically dosed compounded semaglutide (injection) |
| Starting price | Get Started Online for Just $39 | $199/month flat at every dose |
| Pricing model | Entry fee $39; ongoing branded medication pricing varies | Flat $199/month with no step-up fees |
| Clinician access | Licensed clinician review required for treatment | 24/7 U.S. doctor access and virtual check-ins |
| Regulatory note | Offers FDA-approved finished medication; notes compounded meds are not FDA-reviewed | Compounded medications; notes compounded meds are not FDA-reviewed |
U.S. sourcing and platform positioning
Ro.co positions itself as the only mainstream platform in the comparison offering the Wegovy pill, which the source frames as significant for patients who are injection-averse. TMates emphasizes U.S.-formulated compounded medications and licensed coverage in all 50 states, offering a domestic sourcing reassurance for its compounded product.
Which to choose: final guidance for Ro.co vs TMates
Choose Ro.co if you prioritize access to an FDA-approved oral GLP-1 and prefer a branded finished medication with clinician review and upfront pricing disclosure. Choose TMates if you prefer a predictable flat $199/month price that does not increase with higher doses, want 24/7 access to U.S.-based doctors, and are comfortable with clinically dosed compounded semaglutide formulated in U.S. facilities.
Both platforms note that treatment is subject to clinician review and that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.